Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.37 |
| ▸ | RHOA | P61586 | 3/20 | 0.37 |
| ▸ | RHOC | P08134 | 2/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863510 | 0.87 | EPHX2 (0.45) | EPHX2CXCR3GAARHOARHOC | |
| SCHEMBL6862576 | 0.85 | EPHX2 (0.44) | EPHX2CXCR3GAARHOARHOC | |
| SCHEMBL6863997 | 0.84 | EPHX2 (0.47) | EPHX2CXCR3GAARHOARHOC | |
| SCHEMBL6863250 | 0.82 | EPHX2 (0.62) | EPHX2CXCR3 | |
| SCHEMBL12014293 | 0.81 | CXCR3 (0.46) | MGLLEPHX2CXCR3BCHEHDAC3 | |
| SCHEMBL12005298 | 0.78 | S1PR2 (0.44) | EPHX2 | |
| SCHEMBL12015274 | 0.77 | LMNA (0.40) | EPHX2 | |
| SCHEMBL12014292 | 0.75 | EPHX2 (0.42) | MGLLEPHX2CXCR3BCHEHDAC3 | |
| SCHEMBL12014291 | 0.74 | MGLL (0.46) | MGLLCXCR3GAABCHEMAOB | |
| SCHEMBL4279051 | 0.74 | CXCR3 (0.44) | EPHX2CXCR3GAARHOARHOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | MGLL 1142/4885EPHX2 3610/4885CXCR3 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.